Stories by Ingmar Hoerr

Ingmar Hoerr is co-founder and CEO of CureVac, an integrated biopharmaceutical company in the field of novel vaccines for infectious diseases and cancer. CureVac has secured about €65 million in equity financing in three financing rounds and currently employs more than 100 people. During his scientific career, Ingmar laid the foundation of CureVac's unique RNA-based technology platform, RNActive®, enabling the development of a new class of cancer vaccines. With a background in both biology and business management, he decided to set-up CureVac in order to advance his findings to their full therapeutic and commercial potential. Ingmar Hoerr's scientific track record includes works in the laboratories of Professor Günther Jung and Professor Hans-Georg Rammensee, both renowned scientists in organic chemistry and immunology, respectively. As well as one year of field studies on leprosy and HIV in collaboration with the World Health Organization (WHO) at Madurai Kamaraj University, India. Ingmar Hoerr received his PhD in biology from Tübingen University (1999), and a MBA from Danube University in Krems, Austria (2001).